Ratings Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Market Closed - Australian S.E. 02:10:52 2024-04-24 am EDT 5-day change 1st Jan Change
14.88 AUD +4.06% Intraday chart for Telix Pharmaceuticals Limited +18.66% +47.62%

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 103.9 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
+47.62% 3.19B
C+
+1.12% 43.84B
B
+6.77% 41.68B
B-
+45.26% 41.25B
A
-11.96% 27.04B
C
+6.01% 25.53B
B-
-24.92% 18.18B
B
-3.63% 12.29B
C+
+27.16% 12.29B
C+
+7.30% 11.15B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TLX Stock
  4. Ratings Telix Pharmaceuticals Limited